Oculis Holding AG (NASDAQ:OCS) Sees Large Increase in Short Interest

Oculis Holding AG (NASDAQ:OCS) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 34,700 shares, an increase of 38.8% from the February 28th total of 25,000 shares. Based on an average trading volume of 71,500 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.1% of the company’s stock are short sold.

Institutional Investors Weigh In On Oculis

Institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC increased its holdings in Oculis by 12.0% in the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock worth $284,000 after buying an additional 1,800 shares in the last quarter. Bellevue Group AG purchased a new stake in shares of Oculis during the 4th quarter valued at about $170,000. Bank of America Corp DE boosted its holdings in shares of Oculis by 58.2% during the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock valued at $493,000 after acquiring an additional 10,667 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Oculis in the fourth quarter worth approximately $225,000. Finally, Citadel Advisors LLC purchased a new position in shares of Oculis during the fourth quarter valued at approximately $389,000. Institutional investors own 22.30% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on OCS shares. Chardan Capital reiterated a “buy” rating and issued a $28.00 price objective on shares of Oculis in a report on Thursday, March 13th. Robert W. Baird increased their price target on shares of Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a research note on Thursday, March 13th. Finally, HC Wainwright dropped their price objective on shares of Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th.

Oculis Trading Down 1.9 %

NASDAQ OCS opened at $18.66 on Wednesday. The stock’s fifty day moving average price is $20.50 and its 200-day moving average price is $17.62. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. The stock has a market cap of $814.73 million, a P/E ratio of -9.67 and a beta of 0.01. Oculis has a 12 month low of $10.55 and a 12 month high of $23.08.

Oculis (NASDAQ:OCS) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.28). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. As a group, equities analysts forecast that Oculis will post -2.09 EPS for the current fiscal year.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.